"常规发行人要约"计划让宏利可灵活地回购普通股，作为其资本管理策略的其中一环。该策略旨在维持 稳健的监管资本比率，同时兼顾为股东创造价值的目标。 经由"常规发行人要约"计划进行的回购，可通过多伦多证券交易所、纽约证券交易所以及加拿大与美国 的另设交易系统，按回购时的市价或其他获准价格执行。宏利经由"常规发行人要约"购入的所有普通股 将被注销。所有回购交易均须遵守适用的加拿大证券法例及美国联邦证券法例。 来源：新浪港股 宏利金融-S（00945）公布，已获得多伦多证券交易所的批准，启动早前公布的"常规发行人要约"计 划。该计划容许宏利回购并注销最多达4，200万股普通股，相当于宏利已发行流通普通股约2.5%。截 至2026年2月10日，宏利已发行流通普通股共 1，676，751，543股。加拿大金融机构监理处早前已批准 此次"常规发行人要约"计划。 根据"常规发行人要约"计划，宏利在符合多伦多证券交易所相关大额交易规定的前提下，可于任何交易 日在该交易所回购最多1，483，481股宏利普通股，相当于该交易所截至2026年1月31日六个月内平均单 日交易量5，933，925股普通股的25%。经由"常规发行人要约" ...

Core Viewpoint - Manulife Financial Corporation has received approval from the Toronto Stock Exchange to initiate its previously announced "Normal Course Issuer Bid" plan, allowing the company to repurchase and cancel up to 42 million common shares, representing approximately 2.5% of its issued and outstanding common shares [1] Group 1 - The total number of issued and outstanding common shares of Manulife as of February 10, 2026, is 1,676,751,543 shares [1] - Under the "Normal Course Issuer Bid" plan, Manulife can repurchase up to 1,483,481 common shares on any trading day, which is 25% of the average daily trading volume of 5,933,925 common shares over the six months ending January 31, 2026 [1] - The repurchase under the "Normal Course Issuer Bid" can commence on February 24, 2026, and will continue until the bid expires on February 23, 2027, or until the repurchase is completed earlier [1] Group 2 - The repurchases can be executed on the Toronto Stock Exchange, New York Stock Exchange, and other designated trading systems in Canada and the U.S. at market prices or other approved prices [2] - All common shares repurchased by Manulife under the "Normal Course Issuer Bid" will be cancelled [2] - All repurchase transactions must comply with applicable Canadian securities laws and U.S. federal securities laws [2]

经由"常规发行人要约"计划进行的回购，可通过多伦多证券交易所、纽约证券交易所以及加拿大与美国 的另设交易系统，按回购时的市价或其他获准价格执行。宏利经由"常规发行人要约"购入的所有普通股 将被注销。所有回购交易均须遵守适用的加拿大证券法例及美国联邦证券法例。 来源：格隆汇APP 格隆汇2月20日丨宏利金融-S(00945.HK)今日宣布，已获得多伦多证券交易所的批准，启动早前公布 的"常规发行人要约"计划。该计划容许宏利回购并注销最多达4,200万股普通股，相当于宏利已发行流 通普通股约2.5%。截至2026年2月10日，宏利已发行流通普通股共1,676,751,543股。加拿大金融机构监 理处早前已批准此次"常规发行人要约"计划。 根据"常规发行人要约"计划，宏利在符合多伦多证券交易所相关大额交易规定的前提下，可于任何交易 日在该交易所回购最多1,483,481股宏利普通股，相当于该交易所截至2026年1月31日6个月内平均单日交 易量5,933,925股普通股的25%。经由"常规发行人要约"的回购，可由2026年2月24日起在该交易所展 开，直至该要约于2027年2月23日到期，或宏利较早完成回购时为止。 ...

新聞稿 除非另有註明，所有金額均按加元呈列 TSX/NYSE/PSE: MFC SEHK: 945 即時發佈 2026 年2月19日 宏利公佈「常規發行人要約」計劃 加拿大多倫多 – 宏利金融有限公司（「宏利」）今日宣佈，已獲得多倫多證券交易所的批准，啓 動早前公佈的「常規發行人要約」計劃。該計劃容許宏利回購並註銷最多達4,200萬股普通股，相 當於宏利已發行流通普通股約2.5%。截至2026年2月10日，宏利已發行流通普通股共 1,676,751,543股。加拿大金融機構監理處早前已批准此次「常規發行人要約」計劃。 根據「常規發行人要約」計劃，宏利在符合多倫多證券交易所相關大額交易規定的前提下，可於 任何交易日在該交易所回購最多1,483,481股宏利普通股，相當於該交易所截至2026年1月31日六 個月內平均單日交易量5,933,925股普通股的25%。經由「常規發行人要約」的回購，可由2026 年2月24日起在該交易所展開，直至該要約於2027年2月23日到期，或宏利較早完成回購時為 止。 「常規發行人要約」計劃讓宏利可靈活地回購普通股，作為其資本管理策略的其中一環。該策略 旨在維持穩健的監管資本比率， ...

Core Insights - Manulife Financial Corporation (MFC) reported fourth-quarter 2025 core earnings of 80 cents per share, exceeding the Zacks Consensus Estimate by 5.2% and reflecting an 8.1% year-over-year improvement [1][10] Financial Performance - Core earnings totaled $1.4 billion (C$1.9 billion), driven by business growth in Asia, Global Wealth and Asset Management (WAM), and Canada, though partially offset by unfavorable life insurance claims in the U.S. and lower investment spreads [2] - New business value (NBV) for the quarter was $626 million (C$874 million), a 4.1% increase year over year, attributed to a favorable business mix and margin improvements [3] - Annualized premium equivalent (APE) sales decreased by 1% year over year [3] - Wealth and asset management assets under management reached $799.7 billion (C$1,115 billion), marking a 13% year-over-year increase, despite net outflows of $6.8 billion (C$9.5 billion) [4] Segment Performance - Global Wealth and Asset Management's core earnings were $351 million (C$490 million), up 2.3% year over year, supported by higher net fee income and expense discipline [6] - Asia division's core earnings rose to $563 million (C$785 million), a 65% increase year over year, with NBV margin improving to 41.2% [7] - Canada division's core earnings increased to $296 million (C$413 million), up 6.4% year over year, driven by favorable insurance experience and business growth [8] - The U.S. division reported core earnings of $228 million (C$319 million), an 8.5% year-over-year increase, with APE sales and NBV rising by 9% and 8%, respectively [9] Return Metrics - Core return on equity expanded by 60 basis points year over year to 17.1% [5] - Adjusted book value per common share increased by 5.5% year over year to $38.27 [5] Dividend Update - The board approved a 10.2% increase in the quarterly dividend to 48.5 cents, payable to shareholders of record as of February 25, 2026 [11]

Manulife Financial (NYSE:MFC) Q4 2025 Earnings call February 12, 2026 08:00 AM ET Company ParticipantsBrooks Tingle - President and CEO of John HancockColin Simpson - CFODarko Mihelic - Managing DirectorGabriel Dechaine - Managing DirectorHung Ko - Head of Investor RelationsJohn Aiken - Director of ResearchNaveed Irshad - President and CEOPaul Lorentz - President and Global CEOPhilip Witherington - President and CEOStephanie Fadous - Chief ActuarySteven Finch - Chief ActuaryTrevor Kreel - Chief Investment O ...

Manulife Financial (NYSE:MFC) Q4 2025 Earnings call February 12, 2026 08:00 AM ET Company ParticipantsBrooks Tingle - President and CEO of John HancockColin Simpson - CFOHung Ko - Head of Investor RelationsJohn Aiken - Director of ResearchNaveed Irshad - Head of North America and Head of Long-Term CarePaul Lorentz - President and Global CEOPhilip Witherington - President and CEOSteven Finch - Chief ActuaryTrevor Kreel - Chief Investment OfficerConference Call ParticipantsDoug Young - Senior Equity AnalystGa ...

Financial Data and Key Metrics Changes - Manulife reported strong financial results for 2025, with new business CSM growth exceeding 20% in each insurance segment, contributing to double-digit growth in CSM balance and supporting future earnings potential [4][5] - Core EPS grew by 8% year-over-year, with core ROE expanding by 30 basis points from the prior year, tracking well towards the 2027 target of 18%+ [5][24] - The company generated $6.4 billion in remittances and returned nearly $5.5 billion to shareholders, with a LICAT ratio of 136% and a leverage ratio of 23.9% [5][25] Business Line Data and Key Metrics Changes - Global WAM experienced net outflows of $9.5 billion in the second half of 2025, but continued to deliver strong margins and core earnings growth [4][15] - In Asia, APE sales decreased by 3% year-over-year, but new business CSM and new business value delivered strong double-digit growth, with NBV margin expanding by 5.5 percentage points to 41.2% [19][20] - The U.S. segment saw a 9% increase in APE sales, with new business CSM growing by 34%, although core earnings decreased by 22% due to lower investment spreads and unfavorable life insurance claims experience [23] Market Data and Key Metrics Changes - The company reported strong growth in Asia, with APE sales showing double-digit growth in Japan and other Asian markets, despite a decline in Hong Kong sales due to regulatory changes [19][20] - In Canada, APE sales and new business value increased by 2% and 4% respectively, driven by strong growth in individual insurance and annuity sales [21][22] - The U.S. market showed broad-based demand for products, contributing to a significant increase in new business CSM [23] Company Strategy and Development Direction - Manulife introduced a refreshed enterprise strategy focused on growth and customer choice, with strategic investments made to strengthen the portfolio [6][8] - The company aims to become an AI-powered organization, investing in AI to enhance efficiency and customer experience, ranking first among global life insurers for AI maturity [12] - Strategic acquisitions, such as Comvest Credit Partners and a joint venture in India, are part of the company's growth strategy [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic and geopolitical uncertainties due to the diversified nature of the business [4] - The company anticipates continued growth in core earnings and is optimistic about achieving its 2027 targets, despite challenges in specific markets [14][24] - Management highlighted the importance of maintaining a balanced, diversified business model to support sustainable growth [8][9] Other Important Information - The company announced a 10% increase in its quarterly common share dividend and received approval for a new NCIB program to repurchase up to 42 million shares [5][6] - Adjusted book value per share grew by 6% year-over-year, reflecting strong capital position despite significant capital returns to shareholders [25] Q&A Session Summary Question: Clarification on Hong Kong sales and regulatory changes - Management noted that while there was a decline in Hong Kong sales due to regulatory changes, the overall performance for the year was strong, with expectations for recovery as brokers adjust [27][30] Question: Increase in NBV margin in Hong Kong - The increase in NBV margin was attributed to a shift in sales mix, with stronger performance in higher-margin channels [34][36] Question: Impact of eMPF on GWAM earnings and Comvest acquisition - Management indicated that Comvest is expected to contribute positively to AUMA and core earnings, with optimism about customer demand [39] Question: Concerns about mortality experience in the U.S. - Management clarified that recent mortality experience variability is not indicative of a long-term trend and expressed confidence in the normalization of claims experience [44][46] Question: Achieving 18%+ Core ROE target - Management remains confident in reaching the 18%+ Core ROE target by 2027, with various strategies in place to optimize capital deployment and growth [48][50]

Fourth Quarter and Full Year 2025 Financial & Operating Results February 12, 2026 Caution regarding forward-looking statements From time to time, MFC makes written and/or oral forward-looking statements, including in this document. In addition, our representatives may make forward-looking statements orally to analysts, investors, the media and others. All such statements are made pursuant to the "safe harbour" provisions of Canadian provincial securities laws and the U.S. Private Securities Litigation Refor ...

Core Viewpoint - Manulife Financial Corporation (00945) plans to initiate a "normal course issuer bid" subject to approval from the Toronto Stock Exchange, allowing the company to repurchase and cancel up to 42 million common shares, representing approximately 2.5% of its issued and outstanding common shares [1] Group 1 - The "normal course issuer bid" has been approved by the Office of the Superintendent of Financial Institutions Canada [1] - As of January 31, 2026, Manulife has a total of 1.6767 billion issued and outstanding common shares [1] - The repurchase plan is part of Manulife's capital management strategy aimed at maintaining a robust regulatory capital ratio while also creating value for shareholders [1]